{"nctId":"NCT00997035","briefTitle":"The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo","startDateStruct":{"date":"2010-05"},"conditions":["Corneal Ulcer","Eye Infections, Fungal"],"count":240,"armGroups":[{"label":"Oral Voriconazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Voriconazole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Voriconazole","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Presence of a corneal ulcer at presentation\n* Evidence of filamentous fungus on smear (KOH wet mount, Giemsa, or Gram stain)\n* Visual acuity worse than 6/120 (20/400, logMAR 1.3)\n* The patient must be able to verbalize a basic understanding of the study after it is explained to the patient, as determined by physician examiner. This understanding must include a commitment to return for follow-up visits.\n* Willingness to be treated as an inpatient or to be treated as an outpatient and return every 3 days +/- 1 day until re-epithelialization and every week to receive fresh medication for 3 weeks\n* Appropriate consent\n\nExclusion Criteria:\n\n* Evidence of bacteria on Gram stain at the time of enrollment\n* Evidence of acanthamoeba by stain\n* Evidence of herpetic keratitis by history or exam\n* Corneal scar not easily distinguishable from current ulcer\n* Age less than 16 years (before 16th birthday)\n* Bilateral ulcers\n* Previous penetrating keratoplasty in the affected eye\n* Pregnancy (by history or urine test) or breast feeding (by history)\n* Known liver disease, including hepatitis or cirrhosis (Child-Pugh A-C)\n* Acuity worse than 6/60 (2/200) in the fellow eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA 6/60 or better qualifies for enrollment)\n* Acuity better than 6/120 (20/400) in the study eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA can be used for enrollment)\n* Currently on rifampin, rifabutin, ritonavir, long acting barbiturates, phenytoin, carbamazepine, or other drugs known to interact with voriconazole\n* Known allergy to study medications (antifungal or preservative)\n* No light perception in the affected eye\n* Not willing to participate","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Perforation or Therapeutic Penetrating Keratoplasty","description":"Hazard ratio of perforation or therapeutic penetrating keratoplasty (TPK) comparing voriconazole to placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0095562","spread":null},{"groupId":"OG001","value":"0.011204","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Spectacle-corrected logMAR Visual Acuity","description":"Best spectacle-corrected logMAR visual acuity at 3 months after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".7852594","spread":".1083858"},{"groupId":"OG001","value":".787141","spread":".1646131"}]}]}]},{"type":"SECONDARY","title":"Best Spectacle-corrected logMAR Visual Acuity at 3-weeks","description":"Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".8745454","spread":".1080198"},{"groupId":"OG001","value":".744252","spread":".0964871"}]}]}]},{"type":"SECONDARY","title":"Size of Infiltrate/Scar - 3 Months","description":"Size of infiltrate/scar at 3 months after enrollment, using enrollment infiltrate scar/size as a covariate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".9319315","spread":".06508"},{"groupId":"OG001","value":".697005","spread":".0927"}]}]}]},{"type":"SECONDARY","title":"Size of Infiltrate/Scar","description":"Size of infiltrate/scar at 3 weeks after enrollment, using enrollment infiltrate scar/size as a covariate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".2192398","spread":".1663"},{"groupId":"OG001","value":".7973467","spread":".073885"}]}]}]},{"type":"SECONDARY","title":"Hazard Ratio for Re-epithelialization","description":"Hazard Ratio of re-epithelialization comparing the treatment groups","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".0141123","spread":null},{"groupId":"OG001","value":".0130862","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Cure at 7 Days","description":"Fungal Culture negative at 7 days post treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events","description":"Comparing the number of serious and non-serious adverse events by treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentration of Isolates - Natamycin","description":"Minimum Inhibitory Concentration (MIC) of isolates to natamycin by treatment arm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentration of Isolates - Voriconazole","description":"Minimum Inhibitory Concentration (MIC) of isolates to voriconazole by treatment arm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":["Headache","Increase in hypopyon (increase>2mm)","AST or ALT elevated to twice upper limit of normal","Ulcer not healing after 6 weeks of therapy","Dizziness"]}}}